Clearmind adds fifth site in alcohol trial

Clearmind Medicine Inc., a foreign private issuer, submitted a Form 6-K to furnish a press release about its alcohol use disorder program.

Rhea-AI Filing Summary

Clearmind Medicine Inc., a foreign private issuer, submitted a Form 6-K to furnish a press release about its alcohol use disorder program. The release, dated November 20, 2025, states that Clearmind is accelerating an FDA-approved alcohol use disorder clinical trial by activating a fifth elite global medical site, expanding the network of locations involved in the study. The first paragraph of this press release is incorporated by reference into Clearmind’s existing registration statements on Form F-3 and Form S-8, so it becomes part of those documents for U.S. securities law purposes.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Clearmind Medicine (CMND) report in this Form 6-K?

Clearmind Medicine Inc. reports that it has issued a press release describing how it is accelerating an FDA-approved alcohol use disorder clinical trial by activating a fifth elite global medical site.

What clinical trial is highlighted for Clearmind Medicine (CMND)?

The filing highlights an FDA-approved clinical trial focused on alcohol use disorder, which Clearmind Medicine aims to accelerate through the addition of more high-level medical sites.

What is significant about the fifth elite global medical site for CMND?

The press release states that Clearmind Medicine has activated a fifth elite global medical site, indicating that the company is expanding the number of locations participating in its alcohol use disorder clinical trial.

How is the press release used in Clearmind Medicine’s SEC registrations?

The first paragraph of the press release is incorporated by reference into Clearmind Medicine’s registration statements on Form F-3 and Form S-8, making that information part of those securities offering documents.

Which registration statements are updated by this Clearmind Medicine filing?

The filing incorporates the first paragraph of the press release into Clearmind Medicine’s Form F-3 registration statements with File Nos. 333-275991, 333-270859, 333-273293 and its Form S-8 registration statement with File No. 333-283695.

Who signed this Clearmind Medicine (CMND) Form 6-K?

The Form 6-K was signed on behalf of Clearmind Medicine Inc. by Adi Zuloff-Shani, who is identified as the company’s Chief Executive Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/20/2025 - 08:08 AM EST Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of: November 2025

Commission file number: 001-41557

CLEARMIND MEDICINE INC.

(Translation of registrant’s name into English)

101 – 1220 West 6th Avenue

Vancouver, British Columbia

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒    Form 40-F ☐

CONTENTS

Attached hereto and incorporated herein is the Registrant’s press release issued on November 20, 2025, titled “Clearmind Medicine Accelerate FDA-Approved Alcohol Use Disorder Clinical Trial by Activating Fifth Elite Global Medical Site”.

The first paragraph of the press release attached to this Form 6-K as Exhibit 99.1 is incorporated by reference into the Registrant’s Registration Statements on Form F-3 (File Nos. 333-275991, 333-270859, 333-273293) and Form S-8 (File No. 333-283695), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

1

EXHIBIT INDEX

Exhibit No.
99.1		Press release titled: “Clearmind Medicine Accelerate FDA-Approved Alcohol Use Disorder Clinical Trial by Activating Fifth Elite Global Medical Site”

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Clearmind Medicine, Inc.
	(Registrant)
Date: November 20, 2025	By:	/s/ Adi Zuloff-Shani
	Name:	Adi Zuloff-Shani
	Title:	Chief Executive Officer

3